

MOLECULAR IDENTIFICATION OF RESPIRATORY BOVINE MYCOPLASMA ISOLATED FROM ARABIAN CAMELS IN EGYPT

By

Mona A. Mahmoud¹; Wassif, I. M.¹; El-Sayed, A.A.²; Awad, W.S.A.²;

Heba S. Farag² and Eman A. Noaman¹

¹Department of Animal Health, Desert Research Center, Cairo, Egypt.

²Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine,
Cairo University, Giza, Egypt.

SUMMARY

A total of 369 samples were collected from adult Arabian camels for bacteriological examination of *Mycoplasma* associated with Respiratory signs. A 271 nasal swabs (from 126 diseased and 145 apparently healthy camels) and 98 lung tissues (53 abnormal and 45 apparently normal lungs) were examined bacteriologically and Mycoplasmas were recovered from 67 (18.2 %) samples, which were differentiated using Digitonin sensitivity test into *Mycoplasma* (35) and *Acholeplasma* (32) in percentages of 52.2 and 47.8 % of Mycoplasmas, and of 9.5 and 8.7 % of examined samples, respectively. *Mycoplasma* were differentiated according to biochemical reactions into biochemical groups III, IV and V in percentages of 68.6, 17.1 and 14.3% of isolated *Mycoplasma* and of 6.5, 1.6 and 1.4% of examined samples, respectively. All *Mycoplasma* isolates were identified molecularly on the genus level using PCR for detection of 16S rRNA gene, and on the species level as *M. bovis* and *M. bovirhinis* using PCR for detection of specific 16S rRNA gene for each species. *Mycoplasma* species were recovered from nasal swabs and lung tissues constituted 82.9 and 17.1% from isolated *Mycoplasma* (35), and recovered from nasal swabs, lung tissues and total samples in percentages of 10.7, 6.1 and 9.5 %, respectively. *Mycoplasma* was isolated from diseased and apparently healthy camels in percentages of 7.3 and 11.6 %, respectively. *Mycoplasma bovis* recovered from nasal swabs and lung tissues constituted 91.7 and 8.3% from totally isolated *M. bovis* (24), and recovered from nasal swabs, lung tissues and total samples in percentages of 8.1, 2 and 6.5%, respectively. *Mycoplasma bovis* was isolated from diseased and apparently healthy camels in percentages of 4.5 and 8.4%, respectively. *Mycoplasma bovirhinis* recovered from nasal swabs and lung tissues constituted 33.3 and 66.7% from totally isolated *M. bovirhinis* (6), and recovered from nasal swabs, lung tissues and total samples in percentages of 0.7, 4.1 and 1.6 %, respectively. *Mycoplasma bovirhinis* isolated from diseased and apparently healthy camels in percentages of 1.7 and 1.6%, respectively.

Keywords:

Arabian Camels, Respiratory, Nasal swabs, Lung, Mycoplasma and PCR.

INTRODUCTION

Camel is a multi-purpose animal with a huge productive potential and the most suitable domestic animal for use in climatic extremes (Wernery, 2007). The world's camel population of about 28 million heads, 80% of them lives in Africa, with 60% in the Horn of Africa and Arabian camels (Dromedaries) constitute 94% of the world's camel population (FAOSTAT, 2014 and Yam and Khomeiri, 2015).

Mycoplasmas, belongs to class *Mollicutes*, in which *Mycoplasma* and *Acholeplasma* genera are included (Stipkovits and Kempf, 1996). *Acholeplasma* has no known clear role in the disease occurrence (O' Leary, 1989). *Mycoplasma*, under certain conditions, either solely or with bacteria and/or viruses, may cause health disorders such as pneumonia (Freundt, 1985). *Mycoplasma bovis* and *M. bovirhinis* were isolated from camels suffering from pneumonia (Dardeer and Refat, 2004 and Hala, 2004). *Mycoplasma bovis* is the most pathogenic and important bovine *Mycoplasma* causing severe economic losses worldwide (Kumar et al., 2011 and Maunsell et al., 2011).

Bacteriological isolation and identification of *Mycoplasma* species is difficult and time consuming, therefore molecular identification of *Mycoplasma* using PCR targeting specific genes considered a specific and sensitive method for identification (Rong et al., 2009).

MATERIAL AND METHODS

Animals and samples:

A total number of 369 adult Arabian camels from Northwestern coastal zone and El-Basatain abattoir were examined during the period from August 2014 to June 2016 for respiratory infection caused by *Mycoplasma*. Live camels were examined clinically for presence of respiratory signs as cough and nasal discharges, whereas slaughtered camels were examined for the pathological condition of their lungs.

Examined animals were classified according to health condition into 179 diseased (126 live and 53 slaughtered) and 190 apparently healthy (145 live and 45 slaughtered) camels.

A 271 nasal swabs (from 126 diseased and 145 apparently healthy camels) and 98 lung tissues (53 abnormal and 45 apparently normal lungs) with a total number of 369 samples were collected for bacteriological examination. Lungs showed consolidation, grey and red hepatization considered abnormal.

A sterile cotton swabs were inserted into nostrils of examined camels, immediately inoculated into Modified Hayflick's broth medium (**Rosendal, 1994**). Lung tissues collected from slaughtered camels were packed in sterile plastic bags separately. Samples were transported in an icebox to the laboratory for immediate bacteriological examination or stored in a refrigerator (4°C) or in deep freeze (-20°C) until be examined.

Bacteriological isolation and biochemical identification:

The collected lung tissues were seared in the laboratory using a red-hot spatula, cut open and swab was taken from the cut and inoculated into Modified Hayflick's broth medium.

Swabs from nostrils and lung tissues were cultivated on Modified Hayflick's solid medium (**Rosendal, 1994**) by direct method (samples were spread directly on agar plates) and indirect method (samples were inoculated into broth, which incubated for 3 and 6 days then plated, or re-inoculated in broth which plated after 3 and 6 days incubation).

All plates were incubated at 37°C in humidified candle jar for two weeks and examined microscopically using stereomicroscope (10X, Olympus CKX41) every 2-3 days until "fried egg" colonies appeared, followed by purification of the isolates according to **Sabry and Ahmed (1975)**. Isolated Mycoplasmas colonies were maintained at -20°C either as 2-3 ml aliquots of actively growing broth culture or as agar blocks/strips in a sterile screw capped vials.

Purified Mycoplasmas isolates were tested for Digitonin sensitivity (**Freundt, 1983**) to be differentiated into *Mycoplasma* (Digitonin sensitive, showing 6-10 mm zone of inhibition around Digitonin discs) and *Acholeplasma* (Digitonin resistant, showing no inhibition zone).

Identified isolates as *Mycoplasma* were tested for Arginine utilization, Glucose fermentation (**Sabry, 1968**) and Film and spot formation (**Cottew, 1983**). Classified into 5 biochemical groups (From I to V).

Molecular identification of Mycoplasma species using PCR:

Molecular identification of all biochemically-grouped *Mycoplasma* on the genus level was done using PCR for detection of 16S rRNA gene belonging to all *Mycoplasma*, followed by identification on the species level for detection of specific 16S rRNA gene for each of *M. bovis* and *M. bovirhinis* and *ArcB* gene for *M. putrefaciens*.

Reference strains of *M. bovis* and *M. bovirhinis* (Reference GenBank: NCTC10131 and NCTC10118, respectively, kindly provided from Department of Mycoplasmaology, Animal

Reproduction Research Institute, Giza, Egypt) were used as a positive control for molecular identification.

All biochemically identified *Mycoplasma* isolates and reference strains were subjected to DNA extraction through heating incubated broth culture in a heat block at 100 °C for 10 min., cooling on ice for 10 min., centrifugation at 13,000 rpm for 3 min., the supernatant was aspirated and used as DNA template for PCR (Fan *et al.*, 1995).

Each PCR tube included a mixture of 5 µl master mix (Jena Bioscience, Germany), 1 µl of each specific forward and backward primers (Metabion, Germany), 13 µl PCR grade water (Jena Bioscience, Germany) and 5 µl DNA template, with a total volume of 25 µl. PCR tubes gently mixed, placed in the thermal cycler (Biometra, Germany) for amplification of target genes. Each 10 µl of PCR product from each reaction and 5 µl of a 100 - 1000 Molecular weight DNA marker (Jena Bioscience, Germany) were mixed with 2 µl of gel loading buffer (Jena Bioscience, Germany), electrophoresed in 1.5% agarose gel stained with ethidium bromide for detection of target band. Gel visualized using ultraviolet trans-illuminator (BioRad, USA), photographed using Digital Camera (Sony Cyber-shot, Japan) and analyzed using Gel proanalyzer® v4 to determine the product size. Target genes, specific oligonucleotide primers sequences, DNA amplification programs and product size presented in Table (1).

RESULTS

Bacteriological isolation of 369 nasal swabs and lung tissues collected from diseased and apparently healthy camels was done on Modified Hayflick's solid medium, colonies with a typical "fried-egg" appearance characteristic to Mycoplasmas (Photo 1) were recovered in 67 (18.2 %) samples.

The isolated 67 Mycoplasmas colonies differentiated using Digitonin sensitivity test (Photo 2) into 35 as *Mycoplasma* (Digitonin sensitive) and 32 as *Acholeplasma* (Digitonin resistant) in percentages of 52.2 and 47.8 % of isolated Mycoplasmas, respectively, and in percentages of 9.5 and 8.7% of examined samples, respectively.

The identified 35 *Mycoplasma* isolates were tested for Arginine utilization, Glucose fermentation and Film and spot formation, according to the resulting biochemical reactions *Mycoplasma* differentiated into three biochemical groups (Table 2) identified as groups III, IV and V in percentages of 68.6, 17.1 and 14.3% of the isolated *Mycoplasma*, respectively and in percentages of 6.5, 1.6 and 1.4% of examined samples, respectively. Biochemical groups I and II were unidentified.

All of the 35 *Mycoplasma* isolates, which biochemically-grouped into groups III, IV and V, were molecularly identified on the genus level using PCR for detection of 16S rRNA gene (Photo 3).

Molecular identification on the species level was applied on *Mycoplasma* isolates belong to biochemical groups III (24), IV (6) and V (5) for detection of 16S rRNA gene specific for *M. bovis*, 16S rRNA gene specific for *M. bovirhinis* and *ArcB* gene specific for *M. putrefaciens*, respectively. All isolates belong to groups III and IV were molecularly identified as *M. bovis* (Photo 4) and *M. bovirhinis* (Photo 5) using PCR, respectively, whereas isolates belong to group V were unidentified as *M. putrefaciens* using PCR (Table 2).

The percentages of molecularly identified *Mycoplasma* species recovered from nasal swabs and lung tissues collected from diseased and apparently healthy camels were calculated in relation to the number of isolated *Mycoplasma* of the same species and to the number of the examined samples with consideration of health condition (Table 3).

Mycoplasma species recovered from nasal swabs and lung tissues constituted 82.9 and 17.1% from totally isolated *Mycoplasma* (35), and recovered from nasal swabs, lung tissues and total samples in percentages of 10.7, 6.1 and 9.5%, respectively. *Mycoplasma* isolates were recovered from nasal swabs collected from diseased and apparently healthy camels in percentages of 7.1 and 13.8%, whereas those isolated from lung tissues collected from diseased and apparently healthy camels in percentages of 7.6 and 4.4%, with total *Mycoplasma* isolation percentages of 7.3 and 11.6% from all samples collected from diseased and apparently healthy camels, respectively.

Mycoplasma bovis recovered from nasal swabs and lung tissues constituted 91.7 and 8.3% from all isolated *M. bovis* (24), and were recovered from nasal swabs, lung tissues and total samples in percentages of 8.1, 2 and 6.5%, respectively. *Mycoplasma bovis* isolates were recovered from nasal swabs collected from diseased and apparently healthy camels in percentages of 5.6 and 10.3%, whereas those isolated from lung tissues collected from diseased and apparently healthy camels in percentages of 1.9 and 2.2%, with total *M. bovis* isolation percentages of 4.5 and 8.4% from all samples collected from diseased and apparently healthy camels, respectively.

Mycoplasma bovirhinis recovered from nasal swabs and lung tissues constituted 33.3 and 66.7% from all isolated *M. bovirhinis* (6), and recovered from nasal swabs, lung tissues and total samples in percentages of 0.7, 4.1 and 1.6%, respectively. *Mycoplasma bovirhinis*

isolates were recovered from nasal swabs collected from diseased and apparently healthy camels in percentages of 0 and 1.4%, whereas those isolated from lung tissues collected from diseased and apparently healthy camels in percentages of 5.7 and 2.2%, with total *M. bovirhinis* isolation percentages of 1.7 and 1.6% from all samples collected from diseased and apparently healthy camels, respectively.

Mycoplasma species belong to biochemically identified group V and molecularly unidentified recovered from nasal swabs, lung tissues and total samples in percentages of 1.9, 0 and 1.4%, with total isolation percentages of 1.1 and 1.6% from all samples collected from diseased and apparently healthy camels, respectively.

DISCUSSION

Researches concerned with the ability of camels in resisting commonly known diseases had been well documented, whereas those concerned with *Mycoplasma* infection are still lacking (Almaw and Molla, 2000 and Abbas and Omer, 2005).

Bacteriological isolation of 369 nasal swabs and lung tissues collected from diseased and apparently healthy camels revealed Mycoplasmas in 67 (18.2%) samples, which is nearly similar to those recorded by El-Shabiny *et al.* (1998) and Abd El-Wahed (2001) as 24 and 10.6%, respectively. Dardeer and Refat (2004) and El-Ghazali *et al.* (2011) recorded higher and lower percentages as 78.3 and 0.6%, respectively. Low isolation percentage of Mycoplasmas attributed to the presence of toxic or inhibitory substances in camel's tissue that hinder their cultivation (Taylor-Robinson and Chen, 1983 and Tully and Whitcomb, 1992), in addition to the fastidious nature of many pathogenic *Mycoplasma* species (Mederos-Iriarte *et al.*, 2014 and Tille, 2014).

The isolated 67 Mycoplasmas isolates were differentiated using Digitonin sensitivity test into *Mycoplasma* (35) and *Acholeplasma* (32) in nearly equal percentages of 52.2 and 47.8%, respectively, while Dardeer and Refat (2004) recorded higher isolation percentage (83%) of *Mycoplasma* and lower isolation percentage (17%) of *Acholeplasma*, whereas El-Faki *et al.* (2002) and El-Gmaal (2007) isolated only *Mycoplasma* without recovery of *Acholeplasma* from camels. Differences in isolation percentages may be attributed to the effect of environmental (including laboratory) temperature and relative humidity on the survivability of *Mycoplasma* and *Acholeplasma* (Whittlestone, 1976; Jones and Webster, 1984 and Nagatomo, 2001).

The isolated *Mycoplasma* (n=35) were differentiated according to the resulting biochemical reactions into three biochemical groups III, IV and V in percentages of 68.6, 17.1 and 14.3%, respectively, whereas biochemical groups I and II were unidentified. Group III was recorded in percentages of 12.3, 12.8, 35.9 and 17.7%, whereas Group IV was recorded in percentages of 52, 38.5, 7.7 and 55.6% according to **Abd El-Wahed (2001)**, **Dardeer and Refat (2004)**, **Hala (2004)** and **El-Gmaal (2007)**, respectively, they failed to identify groups II and V, and succeeded to identify group I in percentages of 35.7, 35.3, 35.9 and 26.7%, respectively.

All of the 35 *Mycoplasma* isolates were molecularly identified on the genus level using PCR for detection of 16S rRNA gene. On the species level, *M. bovis* (n=24, 68.6%) and *M. bovirhinis* (n=6, 17.1%) were identified molecularly using PCR for detection of specific 16S rRNA gene for each species. The same gene was targeted by **Dardeer and Refat (2004)**, **Hala (2004)** and **El-Gmaal (2007)** for molecular identification of *M. bovis* and *M. bovirhinis* (isolated from respiratory system of camels) using PCR. None of the tested *Mycoplasma* isolates belong to biochemical group V using PCR targeting *ArcB* gene was identified as *M. putrefaciens* (Table 1 and 2), there was no clear explanation for the failure of molecular identification especially in the absence of reference strain to *M. putrefaciens*.

Mycoplasma that recovered from nasal swabs and lung tissues constituted 82.9 and 17.1% from the totally isolated *Mycoplasma*, which nearly in agreement with **El-Gmaal (2007)**, who recorded isolation percentages of 87.7 and 12.3%, respectively.

Mycoplasma recovered from nasal swabs in percentage of 10.7%, which is nearly in agreement with **Abd El-Wahed (2001)** and disagree with **El-Gmaal (2007)**, where they recorded isolation percentages as 7% and 23.8%, respectively. *Mycoplasma* recovered from lung tissues in percentage of 6.1%, which is nearly in agreement with **El-Faki et al. (2002)** and **El-Gmaal (2007)**, who obtained recovery percentages of 8.2% and 8.8%, respectively. From the totally examined samples *Mycoplasma* were recovered in percentage of 9.5%, as that (9%) obtained by **Abd El-Wahed (2001)**, and lower than that obtained by **El-Faki et al. (2002)** and **El-Gmaal (2007)** who recorded a percentages of 16 and 19.7%, respectively. The somewhat higher isolation percentage from nasal swabs than those recovered from lung tissues may be attributed to early infection and colonization of *Mycoplasma* at nostrils mucosa (**Uhaa et al., 1990 a & b**).

From diseased camels, *Mycoplasma* were recovered from nasal swabs and total samples in a relatively lower percentages (7.1 and 7.3%) than those from apparently healthy camels (13.8 and 11.6%), respectively. The relative lower isolation percentage from diseased animals may be attributed to the fragile nature of *Mycoplasma* in the environment due to lack of cell wall, consequently, a successful infection is restricted to close and repeated aerosol transmission (**Nicholas, 2004**) and also to the commensal nature of *Mycoplasma* which become infective as a result of decreased immunity following stress, resulting in subclinical infection which may be later on turned to clinical infection (**Ruffin, 2001**), in addition to the overgrowth of concurrent secondary bacterial infection and/or antibiotic administration during disease condition (**Nicholas and Ayling, 2003**).

Mycoplasma recovered from pneumonic lungs in relatively higher percentage (7.6%) than that of apparently normal lungs (4.4%). **El-Gmaal (2007), Hasaneen et al. (2013) and Chitgar et al. (2014)**, recovered *Mycoplasma* from pneumonic lungs in percentages of 8.8, 8 and 8.2%, respectively. The relatively higher isolation percentage from pneumonic lungs may be attributed to that, the junction of alveolar duct and gas exchange site is the most susceptible site for *Mycoplasma* colonization than upper respiratory tract (**Caswell and Williams, 2007**) with a concurrent decreased immunity resulting from stress (**Ruffin, 2001**).

Mycoplasma bovis recovered from nasal swabs, constituted 91.7% from total *M. bovis* isolates, whereas **El-Gmaal (2007)** recorded a lower recovery rate (66.7%). *Mycoplasma bovis* live as commensal in upper respiratory tract (**Trevor, 1997**) and most of infected animals show inapparent infection and probably act as a chronic carriers (**Chavez et al., 1995**) and the microorganism easily transmitted between sheep, goats, cattle and camel (**Pitcher and Nicholas, 2005**) and considered as a primary cause of pneumonia (**Mihai et al., 2006**). *Mycoplasma bovis* that recovered from lung tissues, constituted 8.3% from total *M. bovis* isolates, this disagrees with **Hala (2004) and El-Gmaal (2007)** who detected a higher detection rates as 42.1 and 33.3%, respectively. Low isolation rate may be attributed to the required needs of repeated / optimal sampling, optimal sample storage and decrease lapse of time between sampling and laboratory examination (**Nicholas and Ayling, 2003 and Kumar et al., 2011**).

Mycoplasma bovis recovered from nasal swabs in percentage of 8.1%, which is higher than that (1.4%) obtained by **El-Gmaal (2007)**, and recovered from lung tissues in percentage of 2%, which is nearly similar (0.7%) to that obtained by **El-Gmaal (2007)**.

Mycoplasma bovis recovered from total samples in percentage of 6.5%, which disagree with **Abd El-Wahed (2001)**, **Dardeer and Refat (2004)**, **Hala (2004)** and **El-Gmaal (2007)** who recorded isolation percentages as 12.3, 12.8, 35.9 and 2.1%, respectively. Low isolation percentage regarded to low numbers of organisms in the sample as a result of intermittent shedding (**Maunsell et al., 2011**), and the high sensitivity of the microorganism to environmental factors such as transportation, in addition to specific requirements needed during bacteriological cultivation (**Ayling et al., 2004**).

Mycoplasma bovis recovered from nasal swabs collected from diseased and apparently healthy camels in percentages of 5.6 and 10.3%, respectively. The relative higher isolation percentage from apparently healthy attributed to the inapparent or chronic nature of infection and / or antibiotic treatment (**Adegboye et al., 1995**).

Mycoplasma bovis recovered from lung tissues collected from diseased and apparently healthy camels in percentages of 1.9 and 2.2%, respectively. The relative lower isolation percentage from abnormal lungs may be attributed to the poor lung condition and/or gross bacterial contamination that inhibit isolation (**Adegboye et al., 1995**).

Mycoplasma bovis isolated in percentages of 4.5 and 8.4% from total samples collected from diseased and apparently healthy camels, respectively. Apparently healthy camels can harbor *M. bovis* in the respiratory tract without showing clinical signs and shed in nasal discharges for month or years as (**Pfützner, 1990**), consequently, act as source of infection for *M. bovis*, which considered as a primary cause of pneumonia in ruminants (**Dardeer and Refat, 2004; Hala, 2004 and El-Gmaal, 2007**).

Mycoplasma bovirhinis recovered from nasal swabs and lung tissues in percentages of 33.3 and 66.7% from the totally isolated *M. bovirhinis*, respectively, whereas **El-Gmaal (2007)** recorded percentages of 86.5 and 13.5%, respectively. *M. bovirhinis* recovered from nasal swabs, lung tissues and total samples in percentages of 0.7, 4.1 and 1.6% respectively, whereas **El-Gmaal (2007)** recorded percentages of 11, 1.7 and 12.8%, respectively. Different isolation percentages of *M. bovirhinis* may be attributed to immune status of examined animal and the selected isolation method and time used for bacteriological examination (**Abo-Elnaga et al., 2012**).

M. bovirhinis recovered from nasal swabs collected from diseased and apparently healthy camels in percentages of 0 and 1.4%, respectively. Failure of isolation nasal swabs

collected from diseased camels may be due to its opportunistic nature, growth inhibition initiated by other microorganism and / or antibiotic treatment (Nicholas *et al.*, 2008).

Mycoplasma bovirhinis recovered from lung tissues collected from diseased and apparently healthy camels in percentages of 5.7 and 2.2%, respectively, the somewhat higher percentage belong to diseased camels may indicate its pathogenic role in camel (Sabry and Ahmed, 1986). The microorganism isolated in percentages of 1.7 and 1.6% from all samples collected from diseased and apparently healthy camels, respectively.

REFERENCES

- Abbas, B. and Omer, H. (2005):** Review of infectious diseases of the camel. Animal Science. Data base, The Centre for Agriculture and Bioscience International Publishing (CABI) and Veterinary Bulletin, 75: 1-16.
- Abd El-Wahed, M.N. (2001):** Camels Mycoplasma in some Delta Governorates. Ph.D. Thesis (Bacteriology), Faculty of Veterinary Medicine. Zagazig University.
- Abo-Elnaga, T.R.; Gouda, A.S.; Kamel, Y.M.; Mahmoud, M.A. and Osman, W.A. (2012):** Application of the polymerase chain reaction for identification of *Mycoplasma* isolated from aborted She Camel. Global Veterinaria journal, 8: 386-392.
- Adegboye, D.S.; Raspberry, U.; Halbur, P.G.; Andrews, J.J. and Rosenbusch, R.F. (1995):** Monoclonal antibody-based immunohistochemically technique for the detection of *M. bovis* in formalin fixed, paraffin embedded calf lung tissues. Journal of Veterinary Diagnostic Investigations, 7: 261-265.
- Almaw, G. and Molla, B. (2000):** Prevalence and etiology of mastitis in camels (*Camelus dromedarius*) in Eastern Ethiopia. Journal of Camel Practice and Research, 7: 97-100.
- Ayling, R.D.; Bashir Uddin, S.E. and Nicholas, R.A.J. (2004):** *Mycoplasma* species and related organisms isolated from ruminants in Britain between 1990 and 2000, Veterinary Record, 155: 413 - 416.
- Caswell, J.L. and Williams, K.J. (2007):** Respiratory System. In Jubb, Kennedy and Palmer's pathology of domestic animals, 5th ed., Vol II. Edited by Maxie, M.G. Philadelphia, and Elsevier Saunders. pp. 523 - 653.
- Chavez, G.Y.R.; Ros, B.C.; Bolske, G.; Mattsson, J.G.; Fernandez, M.C. and Johansson, K.E. (1995):** In vitro amplification of the 16S rRNA genes from *Mycoplasma bovis* and *Mycoplasma agalactiae* by PCR. Veterinary Microbiology, 47: 183 -190.
- Chitgar, A.; Haghdoost, I.S.; Jamshidian, M. and Hesarakhi, S. (2014):** Prevalence of *Pasteurella multocida* and *Mycoplasma arginini* in dromedary camel (*Camelus dromedarius*) in Iran: the effect of season on *P. multocida* prevalence. Advances in Environmental Biology, 8: 792-796.

- Cottew, G.S. (1983):** Recovery and identification of caprine and ovine mycoplasmas. In Methods in Mycoplasmaology, *Mycoplasma* Characterization. Edited by Razin, S. and Tully, J.G. Academic Press, New York. pp. 109 -114.
- Dardeer, M.A.A. and Refat, M. (2004):** Pathological and microbiological studies on pneumonia associated with *Mycoplasma* in camels Egypt. Journal of Comparative Pathology and Clinical Pathology, 17: 206 -220.
- El-Faki, M.G.; Abbas, B.; Mahmoud O.M. and Kleven S.H. (2002):** Isolation and characterization of *Mycoplasma arginini* from camels (*Camelus dromedarius*) with pneumonia. Comparative Immunology, Microbiology and Infectious Diseases, 25: 49 -57.
- El-Ghazali, F.; Hamid, F.M.; Amal M.M. A. and Shallali, A.A.O. (2011):** Isolation of Mycoplasmas and Sero - surveillance for *Mycoplasma mycoides* subsp. *mycoides* in the Dromedary Camel in Some Areas of the Sudan. The Sudan Journal of Veterinary Research, 26: 13-22.
- El-Gmaal, A.A.A.M. (2007):** The use of recent techniques for Diagnosis and identification of *Mycoplasma* in Camels. Ph. D. in Veterinary Medicine Science. (Bacteriology Immunology and Mycology). Faculty of Veterinary Medicine. Zagazig University.
- El-Shabiny, L.M.; Mohamed, M.A. and Nada, H.S. (1998):** Occurrence of *Mycoplasma* species in camels in Egypt. Veterinary Medicine Journal, 46: 329 -338.
- Fan, H.H.; Kleven, S.H. and Jackwood, M.W. (1995):** Application of polymerase chain reaction with arbitrary primers to strain identification of *Mycoplasma gallisepticum*. Avian Diseases journal, 39: 729 -735.
- FAOSTAT (2014):** Food and Agriculture Organization of the United Nations. Available at <http://faostat.fao.org/site/339/default.aspx> (accessed 26 June 2017).
- Freundt, E.A. (1983):** Principles of *Mycoplasma* classification and taxonomy. In Methods in Mycoplasmaology, *Mycoplasma* Characterization. Edited by Razin, S. and Tully, J.G. Academic Press, New York. pp. 9-13.
- Freundt, E.A. (1985):** Host parasite relationship of *Mycoplasma*. In Infektionen durch mycoplasmatales. Edited by Glystroff, I. Ferdinand Inke Verlag Stuttgart. pp. 58-87.
- Hala, M.A. (2004):** Microbiological studies on respiratory affections in camels. Ph.D. in Veterinary Medicine Science. (Bacteriology Immunology and Mycology). Faculty of Veterinary. Medicine Cairo University.
- Hasaneen, T.H.; Rewash, M.Z. and Abdelaziz, E.E. (2013):** Pathological Studies on the Effect of *Mycoplasma* Infection in Male Dromedary Camels. Egypt. Journal of Comparative Pathology and Clinical Pathology, 26: 187-208.

- Jones, C.D.R. and Webster, A.J.F. (1984):** Relationships between counts of nasopharyngeal bacteria, temperature, humidity and lung lesions in veal calves. *Research in Veterinary Science*, 37: 132-137.
- Kumar, A.; Verma, A.K. and Rahal, A. (2011):** *Mycoplasma bovis*, A Multi Disease Producing Pathogen: An Overview. *Asian Journal of Animal and Veterinary Advances*, 6: 537-546.
- Maunsell, F.P.; Woolums, A.R.; Francoz, D.; Rosenbusch, R.F.; Step, D.J. and Janzen, E.D. (2011):** *Mycoplasma bovis* Infections in Cattle. *Journal of Veterinary Internal Medicine*, 25: 772-783.
- Mederos - Iriarte, L.E.; Poveda, J.B.; Poveda, C.G.; Vega-Orellana, O.M.; Gutierrez, C.; Corbera, J.A. and Ramirez, A.S. (2014):** *Mycoplasma* detection and isolation from one-humped camels (*Camelus dromedarius*). *Tropical animal health and production*, 46: 1317-1320.
- Mihai, G.; Kenneth, G.B.; Rachel, A.S.; Tony, D.; Beverly, J. and McEwen (2006):** Naturally occurring *Mycoplasma bovis* associated pneumonia and polyarthritis in feedlot beef calves. *Journal of Veterinary Diagnostic Investigation*, 18: 29 - 40.
- Nagatomo, H.; Takegahara, Y.; Sonoda, T.; Yamaguchi, A.; Uemura, R.; Hagiwara, S. and Sueyoshi, M. (2001):** Comparative studies of the persistence of animal mycoplasmas under different environmental conditions. *Veterinary Microbiology*, 82: 223-232.
- Nicholas, R.A. and Ayling, R.D. (2003):** *Mycoplasma bovis*: disease, diagnosis, and control. *Research in Veterinary Science*, 74: 105 -112.
- Nicholas, R.A.J. (2004):** Recent developments in the diagnosis and control of *Mycoplasma* infections in cattle. *Proceedings of the World Buiatrics Congress, Québec, Canada*, www. Ivis. org.
- Nicholas, R.; Ayling, R. and McAuliffe, L. (2008):** Respiratory diseases of small ruminants. *Mycoplasma Diseases of Ruminants. The Centre for Agriculture and Bioscience International Publishing (CABI)*, p. 171-179.
- O' Leary, M, W. (1989):** *Practical Handbook of Microbiology*. CRC press LLC. pp. 237.
- Peyraud, A.; Woubit, S.; Poveda, J.B.; De la Fe, C.; Mercier, P. and Thiaucourt, F. (2003):** A specific PCR for the detection of *Mycoplasma putrefaciens*, one of the agents of the contagious agalactia syndrome of goats. *Molecular and Cellular Probes journal*, 17: 289 - 294.
- Pfützner, H. (1990):** Epizootiology of *Mycoplasma bovis* infection of cattle. *Proceedings of the 7th Congress of the International Organization for Mycoplasmaology*, vol. 20. Gustav Fisher Verlag, Stuttgart, Germany, p. 394 -399.
- Pitcher, D.G. and Nicholas, R.A. (2005):** *Mycoplasma* host specificity: Fact or fiction. *The Veterinary Journal*, 170: 300 -306.

- Rong, Q.Z.; Kui, N.; Zuo, Y.Z. and Hong, L.L. (2009):** Phylogenetic analysis of *Mycoplasma suis* isolates based on 16S rRNA gene sequence in China. *Veterinary Research Communications*, 33: 855 - 863.
- Rosendal, S. (1994):** Ovine and caprine mycoplasmas. In *Mycoplasmosis in animals: laboratory diagnosis*. Edited by Whitford, H.W.; Rosenbusch; R.F. and Lauerman, L.H. Iowa State University press, Ames. pp. 84 - 95.
- Ruffin, D.C. (2001):** *Mycoplasma* infections in small ruminants. *Veterinary Clinics: Food Animal Practice*, 17: 315 - 332.
- Saad, M. and Abdel Hameed, K.G. (2012):** Detection of *Mycoplasma* species in raw milk of lactating animals in Assiut and Qena city of Egypt. *Veterinary World*, 5: 80 - 85.
- Sabry, M. Z. (1968):** Characterization and classification of avian mycoplasma. Ph. D. Thesis, Faculty of Graduate School, Cornell University, USA.
- Sabry, M.Z. and Ahmed, A.A. (1975):** Evaluation of media and cultural procedures for the primary isolation of mycoplasmas from female genitalia of farm animals. *Journal of Egyptian Veterinary Medical Association*, 35: 18 -34.
- Sabry, M.Z. and Ahmed, A.A. (1986):** Studies on *Mycoplasma* of camel in Egypt: I. primary isolation of mycoplasmas from one-humped camels (*Camelus dromedarius*). II.Characterization and identification of camel mycoplasmas. *Journal of the Egyptian Veterinary Medical Association*, 49: 253 - 280.
- Stipkovits, L. and Kempf, I. (1996):** Mycoplasmosis in poultry. *Revue scientifique et technique (International Office of Epizootics)*, 15:1495 - 1525.
- Taylor-Robinson, D. and Chen, T.A. (1983):** Growth inhibitory factors in animal and plant tissues. In *Methods in Mycoplasmology, Mycoplasma Characterization*. Edited by Razin, S. and Tully, J.G. Academic Press, New York. pp. 109 -114.
- Tille, P.M. (2014):** Bailey and Scott are Diagnostic Microbiology, 13th ed, Mosby, Inc., an affiliate of Elsevier Inc.
- Trevor, R.(1997):**Dairy calf pneumonia, the disease and its impact. *Dairy calf pneumonia, the disease and its impact. Veterinary Clinics of North America: Small Animal Practice*, 13: 379 -391.
- Tully, J.G. and Whitcomb, R.F. (1992):** The genus Spiro plasma. In *the prokaryotes*. Edited by Balows, A.; Truper, H.G.; Dworkin, M.; Harder, W. and Schleifer, K.H. Springer-Verlag, New York. pp. 1960 -1980.
- Uhaa, I.J.; Riemann, H.P.; Thurmond, M.C. and Franti, C.E. (1990a):** A cross-sectional study of bluetongue virus and *Mycoplasma bovis* infections in dairy cattle: I. The association between positive antibody response and production efficiency. *Veterinary Research Communications*, 14: 461- 470.

- Uhaa, I.J.; Riemann, H.P.; Thurmond, M.C. and Franti, C.E. (1990b):** A cross-sectional study of bluetongue virus and *Mycoplasma bovis* infections in dairy cattle: II. The association between a positive antibody response and reproduction performance. *Veterinary Research Communications*, 14: 471- 480.
- Wernery, U. (2007):** Camel milk-new observations. *Proceedings of the International Camel Conference “Recent Trends in Camelids Research and Future Strategies for Saving Camels”*, Rajasthan, India, 16-17 February, 2007; p. 200 - 204.
- Whittlestone, P. (1976):** Effect of climatic conditions on enzootic pneumonia of pigs. *International Journal of Biometrics*, 20: 42 - 48.
- Yam, B.A.Z. and Khomeiri, M. (2015):** Introduction to Camel origin, history, raising, characteristics, and wool, hair and skin, A Review. *Research Journal of Agriculture and Environmental Management*, 4: 496-508.

MOLECULAR IDENTIFICATION OF RESPIRATORY

Table (1): *Mycoplasma* species, target genes, oligonucleotide primer sequences, DNA amplification programs, product sizes and references.

Mycoplasma Species	Target gene	Oligonucleotide primer sequence (5'-3')	Target DNA amplification program					product size (bp)	Reference	
			Initial denaturation Temp (°C) / Time (min)	Second step			Final extension Temp (°C) / Time (min)			
				Denaturation Temp (°C) / Time (sec)	Annealing	Extension				No. of cycles
<i>Mycoplasma</i>	16S rRNA	F: GGG AGC AAA CAG GAT TAG ATA CCC T R: TGC ACC ATCT GTC ACT CTG TTA ACC TC	94/2	94/30	52/60	72/150	30	72/5	270	Abo-Elnaga <i>et al.</i> , 2012
<i>M. bovis</i>	16S rRNA	F: GCA ATA TCA TAG CGG CGA AT R: TCT CAA CCC CGC TAA ACA TC	94/2	94/30	52/60	72/150	30	72/5	227	Abo-Elnaga <i>et al.</i> , 2012
<i>M. bovirhinis</i>	16S rRNA	F: ATT ACT CGG GCA GTC TCC R: GCT GAT AGA GAG GTC TAT CG	94/9	94/30	60/60	72/60	35	72/7	316	Saad and Abdel Hameed, 2012
<i>M. putrefaciens</i>	<i>ArcB</i>	F: AAA TTG TTG AAA AAT TAG CGC GA R: CAT ATC ATC AAC TAG ATT AAT AGT AGC ACC	94/10	94/15	52/15	72/15	35	72/10	316	Peyraud <i>et al.</i> , 2003

Table (2): Biochemical and Molecular identification of isolated *Mycoplasma* species.

Biochemical tests			Biochemical Group	Identification of <i>Mycoplasma</i> species by						
Arginine utilization	Glucose fermentation	Film and spot formation		Biochemical identification			Molecular identification (PCR)			
				Species name (s)	No.	%1	%2	Target gene	Result	No.
+	-	-	I	<i>M. alkalescens</i> <i>M. arginini</i>	0	0	0	<i>Not tested</i>		
+	+	-	II	<i>M. capricolum</i> subsp <i>capricolum</i>	0	0	0	<i>Not tested</i>		
-	-	+	III	<i>M. bovis</i>	24	68.6	6.5	16S rRNA	Positive	24
				<i>M. agalactiae</i>				<i>Not tested</i>		
-	+	-	IV	<i>M. bovirhinis</i>	6	17.1	1.6	16S rRNA	Positive	6
				<i>M. dispar</i> <i>M. ovipneumoniae</i>				<i>Not tested</i>		
-	+	+	V	<i>M. putrefaciens</i>	5	14.3	1.4	<i>Tested and unidentified</i>		
				<i>M. bovoculi</i>				<i>Not tested</i>		
				<i>Mycoplasma</i>	35	100	9.5	16S rRNA	Positive	35


Percentages calculated in relation to the total number (35) of isolated *Mycoplasma* species (%1) and to the total number (369) of examined samples (%2).

Table (3): *Mycoplasma* species isolated from nasal swabs and lung tissues collected from diseased and apparently healthy camels molecularly identified using PCR.

Samples and health condition			<i>Mycoplasma</i> species			
			<i>M. bovis</i>	<i>M. bovirhinis</i>	Unidentified <i>Mycoplasma</i> spp.	Total <i>Mycoplasma</i>
Nasal swabs	Diseased (126)	N	7	0	2	9
		%1	29.2		40	25.7
		%2	5.6		1.6	7.1
	Apparently healthy (145)	N	15	2	3	20
		%1	62.5	33.3	60	57.1
		%2	10.3	1.4	2.1	13.8
	Total (271)	N	22	2	5	29
		%1	91.7	33.3	100	82.9
		%2	8.1	0.7	1.9	10.7
Lung tissues	Diseased (53)	N	1	3	0	4
		%1	4.2	50		11.4
		%2	1.9	5.7		7.6
	Apparently healthy (45)	N	1	1	0	2
		%1	4.2	16.7		5.7
		%2	2.2	2.2		4.4
	Total (98)	N	2	4	0	6
		%1	8.3	66.7		17.1
		%2	2	4.1		6.1
All samples	Diseased (179)	N	8	3	2	13
		%1	33.3	50	40	37.1
		%2	4.5	1.7	1.1	7.3
	Apparently healthy (190)	N	16	3	3	22
		%1	66.7	50	60	62.9
		%2	8.4	1.6	1.6	11.6
	Total (369)	N	24	6	5	35
		%1	100	100	100	100
		%2	6.5	1.6	1.4	9.5

Percentages calculated in relation to the number of isolated *Mycoplasma* of the same species (%1) and to the number of examined samples (%2) with consideration of health condition.

MOLECULAR IDENTIFICATION OF RESPIRATORY



Photo(1):Characteristic“fried-egg”appearance of mycoplasmas colonies under stereomicroscope (10X).



Photo(2):Digonin sensitivity test: Positive (*Mycoplasma*, Left) and Negative (*Acholeplasma*, Right).




Photo (3): PCR product of 16S rRNA gene specific for *Mycoplasma*. Lane M: A 100-1000 bp DNA ladder. Lanes 1-12: Positive samples at 270 bp. Lane +ve: Positive control. Lane -ve: Negative control.




Photo (4): PCR product of 16S rRNA gene specific for *M. bovis*. Lane M: A 100-1000 bp DNA ladder. Lanes 1-12: Positive samples at 227 bp. Lane +ve: Positive control. Lane -ve: Negative control.




Photo (5): PCR product of 16S rRNA gene specific for *M. bovirhinis*. Lane M: A 100-1000 bp DNA ladder. Lanes 1-6: Positive samples at 316 bp. Lane +ve: Positive control. Lane -ve: Negative control.

التصنيف الجزيئي لميكوبلازما الجهاز التنفسي للماشية المعزولة من الإبل العربية في مصر

منى عبد الله محمود¹، إسلام محمد وصيف¹، عمرو عبد العزيز السيد²، وليد سيد أحمد عوض²، هبة سعيد فرج²

و إيمان عبد التواب نعمان¹

¹ قسم صحة الحيوان، مركز بحوث الصحراء، القاهرة، مصر.

² قسم الأمراض الباطنة والمعدية، كلية الطب البيطري، جامعة القاهرة، الجيزة، مصر.

الملخص العربي

تم تجميع 369 عينة من الإبل العربية البالغة للفحص البكتريولوجي للميكوبلازما المصاحبة للأعراض التنفسية. تم إجراء الفحص البكتريولوجي لعدد 271 مسحة أنفية (من 126 جمل مريض و145 سليم ظاهريا) و98 أنسجة رئوية (53 رئة مصابة و45 سليمة ظاهريا). تم عزل الميكوبلازما من 67 (18.2%) عينة وباستخدام إختبار الحساسية للديجوتنين تم تحديد الميكوبلازما في 35 عينة و الأكيلوبلازما في 32 عينة بنسبه 52.2% و 47.8% من الميكوبلازما على الترتيب وبنسبه 9.5% و 8.7% من العينات التي تم فحصها على الترتيب. تم تقسيم الميكوبلازما باستخدام التفاعلات البيوكيميائية إلى المجموعات الحيويه الثالثة والرابعة والخامسة بنسبه 68.6%، 17.1%، 14.3% من الميكوبلازما المعزولة على الترتيب وبنسبه 6.5% و 1.6% و 1.4% من العينات التي تم فحصها على الترتيب. تم إجراء التعرف الجزيئي لجنس الميكوبلازما باستخدام تفاعل البلمرة المتسلسل بالبحث عن جين 16S rRNA كما تم إجراء التعرف الجزيئي لنوع الميكوبلازما بوفس وبوفيرينس بالبحث عن جين 16S rRNA المتخصص لكل من نوعي الميكوبلازما. تم تحديد نسبة الميكوبلازما المعزولة من المسحات الأنفية و أنسجة الرئة ب 82.9% و 17.1% من إجمالي (35) الميكوبلازما المعزولة على الترتيب وبنسبة 10.7%، 6.1%، 9.5% من المسحات الأنفية والرئة و إجمالي العينات على الترتيب. تم تحديد نسبة الميكوبلازما المعزولة من العينات التي تم جمعها من الإبل المريضة والسليمة ظاهريا ب 7.3% و 11.6% على الترتيب. تم عزل الميكوبلازما بوفس من المسحات الأنفية و أنسجة الرئة بنسبة 91.7% و 8.3% من إجمالي الميكوبلازما بوفس المعزولة (24) على الترتيب ومن المسحات الأنفية والرئة و إجمالي العينات بنسبه 8.1% و 2% و 6.5% على الترتيب ومن العينات التي تم جمعها من الإبل المريضة والسليمة ظاهريا بنسبه 4.5% و 8.4% على الترتيب. تم عزل الميكوبلازما بوفيرينس من المسحات الأنفية و أنسجة الرئة بنسبة 33.3% و 66.7% من إجمالي الميكوبلازما بوفيرينس المعزولة (6) على الترتيب ومن المسحات الأنفية والرئة و إجمالي العينات بنسبه 0.7% و 4.1% و 1.6% على الترتيب ومن العينات التي تم جمعها من الإبل المريضة والسليمة ظاهريا بنسبه 1.7% و 1.6% على الترتيب.